Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Evaxion Biotech ( (EVAX) ) is now available.
Evaxion A/S, a Danish clinical-stage TechBio firm focused on AI-designed cancer and infectious disease vaccines, is advancing a pipeline that spans personalized and off-the-shelf oncology candidates along with prophylactic programs. Its AI-Immunology platform underpins rapid target discovery, drug design and development, supported by a team of more than 40 specialists across the value chain.
On March 17, 2026, Evaxion announced that two abstracts based on its AI-Immunology platform were accepted for presentation at the AACR Annual Meeting in San Diego, running April 17-22, 2026. The work features new phase 2 biomarker and immunogenicity data for its personalized melanoma vaccine EVX-01, tested with Merck’s KEYTRUDA, and an ERV‑neoantigen strategy for glioblastoma, moves that highlight its clinical progress and partnering ambitions ahead of its participation in AACR’s Oncology Industry Partnering event.
The most recent analyst rating on (EVAX) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Copenhagen-based clinical-stage TechBio company that uses its proprietary AI-Immunology platform to design novel vaccines for cancer and infectious diseases. Leveraging artificial intelligence to decode the human immune system, the company develops both personalized and off-the-shelf cancer vaccines, as well as prophylactic candidates that target high unmet medical needs across multiple indications.
Average Trading Volume: 63,767
Technical Sentiment Signal: Sell
Current Market Cap: $31.86M
See more data about EVAX stock on TipRanks’ Stock Analysis page.